Evidence map›Paper›PMID 35756651›Full record

ArticleFrontiers in oncology2022

Racial Disparities in Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: Does Aggressive Surgical Treatment Overcome Cancer Health Inequities?

Devon C Freudenberger, Xiaoyan Deng, Vignesh Vudatha, Andrea N Riner, Kelly M Herremans, Dipankar Bandyopadhyay, Leopoldo J Fernandez, Jose G Trevino

Open access · goldAbstract read
In one paragraph

Article in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Devon C FreudenbergerDivision of Surgical Oncology, Department of Surgery, Virginia Commonwealth University School of Medicine, Richmond, VA, United States.
Xiaoyan DengDepartment of Biostatistics, Virginia Commonwealth University School of Medicine, Richmond, VA, United States.
Vignesh VudathaDivision of Surgical Oncology, Department of Surgery, Virginia Commonwealth University School of Medicine, Richmond, VA, United States.
Andrea N RinerDepartment of Surgery, University of Florida College of Medicine, Gainesville, FL, United States.
Kelly M HerremansDepartment of Surgery, University of Florida College of Medicine, Gainesville, FL, United States.
Dipankar BandyopadhyayDepartment of Biostatistics, Virginia Commonwealth University School of Medicine, Richmond, VA, United States.
Leopoldo J FernandezDivision of Surgical Oncology, Department of Surgery, Virginia Commonwealth University School of Medicine, Richmond, VA, United States.
Jose G TrevinoDivision of Surgical Oncology, Department of Surgery, Virginia Commonwealth University School of Medicine, Richmond, VA, United States.
Virginia Commonwealth University · USUniversity of Florida · US

Funding

Training Program for Applied Research and Development in Genomic MedicineT32HG008958 · NHGRI · UNIVERSITY OF FLORIDA · PI Larisa Humma Cavallari, Stephen E. Kimmel · 2018 to 2026
$3.8M
NHGRI NIH HHS T32 HG008958
6 · The paper itself

Abstract

Background: Advanced cancer states perpetuate health-related disparities. Peritoneal-based cancers are clinically advanced cancers that present a significant clinical dilemma. Peritoneal cancers are managed aggressively with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). While racial and ethnic disparities are prevalent in cancer, there are no studies investigating if racial disparities exist in patients with peritoneal carcinomatosis managed with CRS and HIPEC. We hypothesized that this advanced disease state further delineates racial disparities. Methods: A retrospective chart review was conducted on patients with peritoneal carcinomatosis receiving CRS and HIPEC at a single institution from January 1, 2017-October 4, 2021. Descriptive statistics were used to compare racial groups. The Cox Proportional Hazards Model and Log Rank Test were used for multivariate and overall survival analysis. Results: In total, 67 patients underwent CRS and HIPEC, of which 41 (61.2%) were White, 20 (29.8%) were Black, 3 (4.5%) were Asian, and 3 (4.5%) were Other race. When compared to White patients, Black patients had lower income (p=0.0011), higher incidence of hypertension (p=0.0231), and lower performance status (p=0.0441). Cancer type, including colorectal, appendiceal, ovarian, etc., was similar between groups (p=0.8703). Despite these differences in sociodemographic and morbidity factors, when comparing Black patients to White patients, there were no differences in peritoneal cancer index score (13.2 vs. 12.3, p=0.6932), estimated blood loss (748 vs. 655 mL, p=0.6332), minor/major complication rates (1.1 vs. 1.2, p=0.7281; 0.4 vs. 0.7, p=0.3470, respectively), 30-day readmission rates (25.0% vs. 17.1%, p=0.6210), disease recurrence (40.0% vs. 51.2%, p=0.3667), or 30-day mortality (0.0% vs. 2.4%, p=1.0000). Overall survival was similar for Black and White patients (p=0.2693). The occurrence of a major complication was the only factor associated with overall survival (HR 2.188 [1.502, 3.188], p< 0.0001). Conclusions: Despite differences in patient socioeconomic factors and comorbid conditions, outcomes were similar between Black and White patients receiving CRS and HIPEC at our institution. While larger studies with more diverse patient populations are needed to confirm these findings, our data provide evidence that aggressive surgical management across diverse patient populations allows for equitable outcomes.

Indexed as

cytoreductive surgeryHIPEC (heated intraperitoneal chemotherapy)peritoneal carcinomatosisracial disparitiessurgical outcomes

Identifiers

PMID35756651
PMCPMC9213675
OpenAlexW4281617988

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.